Levental Uri, Bersudsky Yuly, Dwalatzky Tzvi, Lerner Vladimir, Medina Sophie, Levine Joseph
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheva, Israel.
Isr J Psychiatry Relat Sci. 2015;52(1):6-10.
The effects of creatine on brain metabolism and the potential cognitive enhancing properties of this compound raise the possibility of developing a new augmentation therapeutic strategy in schizophrenia especially in patients demonstrating negative and cognitive symptomatology.
Seven inpatients with chronic schizophrenia presenting with treatment resistant negative symptoms were enrolled into exploratory treatment study with creatine monohydrate augmentation at a daily high-dose of 10 grams, administered for 6 months. Several clinical rating scales and a computerized cognitive assessment battery were applied.
Creatine treatment mildly improved the schizophrenia symptomatology but there were no significant changes in cognitive functions. Several ward behaviors were also improved. Tardive parkinsonism improved numerically by above 40% in 4 out of 6 patients.
This small, open design study of high dose creatine add-on for 6 months in chronic inpatients with schizophrenia demonstrated only mild positive effects on the patients' symptomatology and behavior and might have beneficial effect on tardive parkinsonism.
肌酸对大脑代谢的影响以及该化合物潜在的认知增强特性，为开发一种新的增效治疗策略提供了可能性，尤其是在表现出阴性和认知症状的精神分裂症患者中。
七名患有难治性阴性症状的慢性精神分裂症住院患者被纳入一项探索性治疗研究，采用每日10克高剂量一水肌酸进行增效治疗，为期6个月。应用了几种临床评定量表和一套计算机化认知评估测试。
肌酸治疗使精神分裂症症状略有改善，但认知功能无显著变化。一些病房行为也有所改善。6名患者中有4名迟发性帕金森症在数值上改善超过40%。
这项针对慢性精神分裂症住院患者进行的为期6个月的高剂量肌酸附加治疗的小型开放性设计研究，仅对患者的症状和行为显示出轻微的积极影响，并且可能对迟发性帕金森症有有益作用。
